会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • FULLY HUMAN HYBRIDOMA FUSION PARTNER CELL LINES
    • 完全人类融合合作伙伴细胞系
    • WO2008013552A3
    • 2008-08-28
    • PCT/US2006033607
    • 2006-08-25
    • UNIV COLUMBIA
    • TRAKHT ILYAKALANTAROV GAVREEL
    • C07K16/00C12N5/08C12N5/22C12N5/28C12N15/07C12N15/89
    • C12N5/163C07K16/00C07K2317/21
    • Certain aspects of the present invention are directed to new fully human fusion partner cell lines called human Karyochi cells, and to methods for making them. Human Karyochi cells are then fused with human antibody-secreting lymphoid cells to make fully human hybridomas called Karyochi-based hybridomas, which likewise secrete fully human monoclonal antibodies. Human Karyochi cells are made by isolating a donor nucleus that is substantially free of cytoplasm from either a first malignant B-lymphocyte cell line or a normal B-lymphocyte, and transferring the donor nucleus into the cytoplasm of a recipient cell from a second T- or B-lymphoid cell line. With time the nuclei synchronize and fuse to form the chimeric Karyochi fusion partner cell line. Nuclear transfer can be accomplished using intra-cytosolic nucleus injection or by impact-induced nucleus administration.
    • 本发明的某些方面涉及称为人类Karyochi细胞的新的完全人融合伙伴细胞系,以及制备它们的方法。 然后将人类Karyochi细胞与人抗体分泌淋巴样细胞融合以制备完全人类杂交瘤,称为基于核型的杂交瘤,其同样分泌完全的人单克隆抗体。 通过从第一恶性B淋巴细胞细胞系或正常B淋巴细胞中分离基本上不含细胞质的供体核,并将供体核从第二T细胞转移到受体细胞的细胞质中制备人类核型细胞, 或B淋巴细胞系。 随着时间的推移,核同步并融合形成嵌合的Karyochi融合伙伴细胞系。 核转移可以使用胞内核注射或通过冲击诱导的核给药来完成。